|
Gene
|
Alteration
|
Gene
|
Alteration
|
Gene
|
Alteration
|
Gene
|
Alteration
|
|
EGFR
|
SNV, InDel
|
ROS1
|
SNV, InDel, Fusion
|
KRAS
|
SNV, InDel
|
PIK3CA
|
SNV, InDel
|
|
ALK
|
SNV, InDel, Fusion
|
RET
|
SNV, InDel, Fusion
|
NRAS
|
SNV, InDel
|
BRAF
|
SNV, InDel
|
|
HER2
|
SNV, InDel
|
MET
|
SNV, InDel, CNV
|
|
|
|
|
Fast turnaround time within
1 week
Automatic and secure data analysis
Target 10 driver genes for NSCLC/CRC
Detection of SNV, InDel, fusion, CNV
Specifications
cfDNA: ≥10 ng (optimal 30 ng)
Publications
1. Yang, James Chih-Hsin et al. Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial. Journal of Thoracic Oncology, Volume 18, Issue 12, 1743 - 1755.
2. Ren, W.; Zhu, Y.; Wang, Q.; Jin, H.; Guo, Y.; Lin, D. Deep Learning-Based Classification and Targeted Gene Alteration Prediction from Pleural Effusion Cell Block Whole-Slide Images. Cancers 2023, 15, 752.
3. Qiu, D., Xi, H., Wang, M. et al. The debatable role of immune checkpoint blockade therapy in lung adenocarcinoma-oriented liver metastatic malignant lesions. J Cancer Res Clin Oncol 149, 5791–5802 (2023).
4. Cai, Y., Liu, H., Chen, X., Yang, J., & Huang, B. (2023). P40 and TTF‑1 double‑expressing non‑small cell lung cancer with EML4‑ALK and PIK3CA gene mutations: A case report and review of the literature. Oncology Letters, 25, 59.
5. Takamori S, Seto T, Yamaguchi M, Kinoshita F, Fujishita T, Ito K, Toyozawa R, Shoji F and Okamoto T (2022) Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation. Front. Oncol. 12:965741.
6. Ou, Sai-Hong Ignatius et al. Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2). Journal of Thoracic Oncology, Volume 17, Issue 12, 1404 - 1414.
7. Ma Y, Li Q, Du Y, Chen W, Zhao G, Liu X, Li H, Liu J, Shen Z, Ma L, Zhou Y. Oncogenic Genetic Alterations in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China. Cancer Manag Res. 2020;12:10861-10874.
8. Wu, W., Huang, Y., Guo, J., Xie, X., Li, H., Cao, Z., Wei, H. and Wu, C. (2020), Detection and comparison of EGFR mutations from supernatants that contain cell-free DNA and cell pellets from FNA non–small cell lung cancer specimens. Cancer Cytopathology, 128: 545-552.
9. Wu, W., Cao, Z., Zhang, W. et al. Comparison of the SuperARMS and ARMS for detecting EGFR mutations in liquid-based cytology specimens from NSCLC patients. Diagn Pathol 15, 9 (2020).
10. Xu H, Baidoo AA, Su S, Ye J, Chen C, Xie Y, Bertolaccini L, Ismail M, Ricciuti B, Ng CS, Flores RM, Li Y; written on behalf of AME Lung Cancer Collaborative Group. A comparison of EGFR mutation status in tissue and plasma cell-free DNA detected by ADx-ARMS in advanced lung adenocarcinoma patients. Transl Lung Cancer Res 2019;8(2):135-143.
11. Xiuhuan Ji, Nanying Che, Rixu lin, Jianou Chen, Xiuling Wu. Efficient ten-gene analysis of NSCLC tissue samples by next-generation sequencing. Pathology - Research and Practice, Volume 215, Issue 5, 2019, Pages 1066-1070.